证券代码：002424 证券简称：贵州百灵 贵州百灵企业集团制药股份有限公司 投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |----------------|----------------------------------|---------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华创证券有限责任公司：邱旻 | | | 人员姓名 | | | | 时间 | 2017 年 1 月 10 日 | 14：00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事、董事会秘书、总经理：牛民 | | | 员姓名 | 证券事务代表：陈智 | | | 投资者关系活动 | 一、签署《承诺书》 | | | 主要内容介绍 | 二、投资者与公司交流内容 | | | | 1 、向投资者 ...

证券代码：002424 证券简称：贵州百灵 贵州百灵企业集团制药股份有限公司 投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |----------------|----------------------------------|---------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 上海宝源胜知投资管理有限公司 研究员：刘弘毅 | | 人员姓名 | | | | 时间 | 2017 年 7 月 13 | 日 12：30 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事、董事会秘书、总经理：牛民 | | | 员姓名 | 证券事务代表：陈智 | | | 投资者关系活动 | 一、签署《承诺书》 | | | 主要内容介绍 | 二、投资者与公 ...

证券代码：002424 证券简称：贵州百灵 贵州百灵企业集团制药股份有限公司 投资者关系活动记录表 编号：2017-004 | --- | --- | --- | |----------------|--------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华创证券有限责任公司：邱旻 | | | 人员姓名 | | | | 时间 | 2017 年 11 月 3 日 | 15：00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事、董事会秘书、总经理：牛民 | | | 员姓名 | 证券事务代表：陈智 | | | | 一、签署《承诺书》 | | | 投资者关系活动 | 二、投资者与公司交流内容 | ...

证券代码：002424 证券简称：贵州百灵 贵州百灵企业集团制药股份有限公司 投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |----------------|--------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 河南巨坤基金管理有限公司：王峰、王长创 | | 人员姓名 | | | | 时间 | 2018 年 5 月 24 | 日 12： 00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事、董事会秘书、总经理：牛民 | | | 员姓名 | 证券事务代表：陈智 | | | | 一、签署《承诺书》 | | | 投资者关系活动 | 二、投资者与公 ...

Group 1: Investor Relations Activities - The investor relations activity was conducted with specific target research and included various participants from different investment firms [1] - The meeting took place on November 4, 2021, in Shanghai, with key company representatives presenting [2] Group 2: Marketing Network and Sales Strategy - The company has established a marketing network covering over 3,200 first and second-level hospitals across 32 provinces, cities, and autonomous regions [2] - The company has built business relationships with over 80% of terminal customers nationwide, totaling more than 470,000 terminal customers, including 85,000 VIP customers [3] - The marketing team is recognized as a core advantage, contributing to continuous sales growth [2][3] Group 3: Product Development and Research - The company has 17 exclusive苗药 (Miao medicine) products, making it a leader in the industry with the widest market coverage [3] - The company is actively promoting the糖宁通络 (Tang Ning Tong Luo) product through clinical research and partnerships with various medical institutions [4][5] - A national-level research project on糖宁通络 for diabetes treatment has been approved, involving multiple hospitals and experts [5] Group 4: Cost Management and Production Capacity - The company is implementing measures to control raw material costs through centralized procurement and improved production planning [4] - An expansion project initiated in 2020 is expected to increase the company's pre-extraction capacity by 35,000 tons per year, reaching a total capacity of 60,000 tons annually [5][6] - Continuous improvements in production lines and the introduction of advanced automated systems are being pursued to enhance production efficiency [6]

Financial Performance - The company's revenue for Q3 2022 was ¥815,875,375.97, representing a 15.75% increase year-over-year[7]. - The net profit attributable to shareholders decreased by 57.21% to ¥16,759,008.88 for the same period[7]. - The net profit after deducting non-recurring gains and losses was -¥18,506,207.46, a decline of 155.04% compared to the previous year[7]. - Total operating revenue for the third quarter reached ¥2,098,719,854.72, an increase of 6.1% compared to ¥1,978,256,627.57 in the same period last year[30]. - Net profit attributable to the parent company increased to ¥2,203,267,713.08, compared to ¥2,103,074,715.25 in the previous year, marking a growth of 4.8%[29]. - The net profit for the current period is 103,069,157.27, a decrease from 120,536,192.86 in the previous period, representing a decline of approximately 14.5%[32]. - The total profit for the current period is 128,848,046.04, compared to 149,389,471.04 in the previous period, indicating a decrease of about 13.8%[32]. - Operating income for the current period is 128,463,653.36, down from 149,703,030.55, reflecting a decline of approximately 14.2%[32]. - The total comprehensive income attributable to the parent company's owners is 100,193,836.64, down from 120,701,633.45, a decrease of approximately 17%[32]. - The basic and diluted earnings per share for the current period are both 0.07, compared to 0.09 in the previous period, indicating a decline of 22.2%[32]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,650,025,239.72, an increase of 2.48% from the end of the previous year[7]. - The total assets of the company reached ¥6,650,025,239.72, up from ¥6,489,334,127.28, indicating a growth of 2.5%[29]. - The total liabilities increased to ¥2,604,301,267.12 from ¥2,529,138,719.71, representing a rise of 3.0%[29]. - The company's total equity attributable to shareholders reached ¥4,023,947,101.70, compared to ¥3,941,294,696.11, reflecting an increase of 2.1%[29]. - The total liabilities and equity combined amounted to ¥6,650,025,239.72, compared to ¥6,489,334,127.28, showing a growth of 2.5%[29]. Cash Flow - The company's cash flow from operating activities was ¥92,501,686.94, down 69.81% year-over-year[12]. - Cash flow from operating activities for the current period is 92,501,686.94, significantly lower than 306,399,352.57 in the previous period, a decrease of about 69.8%[36]. - Cash flow from investing activities shows a net inflow of 7,808,156.68, a recovery from a net outflow of -161,191,829.10 in the previous period[39]. - Cash flow from financing activities resulted in a net outflow of -202,196,383.47, an improvement from -478,555,753.55 in the previous period[39]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 92,734, with the largest shareholder, Jiang Wei, holding 20.57% of shares, equating to 290,246,284 shares[16]. - The total number of preferred shareholders is not specified, but the report includes details on the top ten preferred shareholders[19]. - Jiang Wei and Jiang Yong are identified as acting in concert, with Jiang Wei holding 20.57% and Jiang Yong holding 3.83% of shares[16]. - The company has a repurchase account holding 13,601,600 shares, which accounts for 0.96% of total shares[20]. Research and Development - Research and development expenses decreased by 44.21% to ¥13,315,151.57 compared to the same period last year[12]. - Research and development expenses for the quarter were ¥13,315,151.57, a decrease of 44.8% from ¥23,868,023.89 in the same quarter last year[30]. Inventory and Receivables - Accounts receivable increased to ¥1,815,776,263.89 from ¥1,573,975,166.17, indicating a growth of approximately 15.4%[22]. - Inventory as of September 30, 2022, stands at ¥1,009,438,442.28, up from ¥844,793,857.87, reflecting a growth of about 19.5%[22]. - The company's total current assets as of September 30, 2022, amount to ¥3,732,342,228.04, an increase from ¥3,530,327,436.87 at the beginning of the year[22]. Investment Income - The investment income increased significantly by 5446.45% to ¥16,149,171.25 due to the transfer of equity in Chengdu Zeling[12]. - The company has made significant investments in long-term equity, totaling ¥1,072,430,272.44, down from ¥1,114,023,667.70[22].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[18]. - Net profit attributable to shareholders reached RMB 300 million, up 10% compared to the same period last year[18]. - The company's operating revenue for the reporting period was ¥1,282,844,478.75, representing a year-on-year increase of 0.74% compared to ¥1,273,366,730.02[25]. - The net profit attributable to shareholders was ¥83,433,988.95, reflecting a growth of 2.37% from ¥81,504,151.60 in the same period last year[25]. - The net profit from non-recurring gains and losses increased by 8.63% to ¥78,449,842.08, up from ¥72,220,250.43[25]. - The company aims to achieve a revenue target of RMB 2.5 billion for the full year 2022, representing a growth of 12% from 2021[18]. - The total operating revenue for the reporting period was approximately ¥1.28 billion, representing a year-on-year increase of 0.74%[81]. - The net cash flow from operating activities decreased significantly by 77.43%, amounting to ¥93,385,802.23 compared to ¥413,702,719.45 in the previous year[25]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 20% increase in sales from this region by the end of 2023[18]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach, with a focus on companies in the biopharmaceutical sector[18]. - The company is actively promoting its integrated traditional medicine project, with coverage expanding to 16 provinces and regions[79]. - The company has established over 3,200 primary and secondary commercial channels nationwide, with more than 470,000 terminal customers and over 85,000 signed VIP customers[76]. Research and Development - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation and new product development[18]. - The company has established a comprehensive technical innovation system and increased R&D investment, actively promoting various R&D projects[61]. - The company is focused on enhancing its R&D capabilities, with multiple innovation platforms established to drive technological advancements[72]. - The company plans to enhance its R&D capabilities and optimize its project selection to improve drug development outcomes[125]. Product Development and Market Position - The company has launched two new OTC products in the first half of 2022, contributing to a 5% increase in market share in the OTC segment[18]. - The company continues to focus on the development and sales of traditional Chinese medicine products, with key products including Yindan Xinnaotong soft capsules and Kesu Ting syrup[38]. - The company is recognized as a key player in the new pharmaceutical industry in Guizhou Province and the largest producer of Miao medicine in China, ranking 18th among the top 20 OTC drug manufacturers in 2021[40]. - The company has 51 products included in the National Medical Insurance Directory, enhancing its market competitiveness[69]. Financial Management and Investments - The company has invested ¥58,872,542 in capacity expansion and technological upgrades, with a cumulative actual investment of ¥217,638,839[93]. - The total committed investment amount for the projects is CNY 35,075.11 million, with an adjusted total investment amount of CNY 50,357.09 million, achieving an investment progress of 99.94%[103]. - The company reported a total of ¥138,790.46 million raised through its initial public offering, with ¥150,763.74 million cumulatively used, representing 77.91% of the total raised[99]. Risk Management - The company identified potential risks including regulatory changes and market competition, and has outlined strategies to mitigate these risks[5]. - The company faces risks related to drug research and development, including the potential for clinical trial failures and regulatory challenges[125]. - The company is facing risks from raw material price fluctuations, which can significantly impact production costs due to various macroeconomic factors[129]. - The company has established a dedicated environmental safety department to oversee environmental protection efforts and ensure compliance with national standards[140]. Environmental and Social Responsibility - The company has fully transitioned to gas boilers, significantly reducing pollutant emissions and has been recognized as a provincial-level environmental protection excellent enterprise[150]. - The company donated emergency supplies worth RMB 5.09 million to support local COVID-19 prevention efforts, including 100,000 masks and 50 tons of disinfectant alcohol[151]. - The company has built traditional Chinese medicine planting bases in several impoverished areas, promoting economic development and increasing farmers' income through the cultivation of medicinal herbs and organic crops[153]. Corporate Governance - The company emphasizes compliance and governance, continuously improving internal controls and risk management capabilities[67]. - The company has not distributed cash dividends or bonus shares for the half-year period and has no plans for capital reserve conversion into share capital[136]. - There were no significant litigation or arbitration matters during the reporting period[168]. - The company did not engage in any significant related party transactions during the reporting period[171].

Financial Performance - The company's operating revenue for Q1 2022 was ¥738,716,135.73, a decrease of 1.91% compared to ¥753,124,230.90 in the same period last year[4] - Net profit attributable to shareholders was ¥65,091,265.16, representing a 4.55% increase from ¥62,256,060.18 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥63,395,941.66, up 12.62% from ¥56,293,131.36 in the previous year[4] - Basic and diluted earnings per share were both ¥0.05, an increase of 25.00% from ¥0.04 year-on-year[4] - Net profit for the current period is ¥65,443,727.95, representing an increase of 5.0% compared to ¥61,914,231.94 in the previous period[28] - Operating profit increased to ¥76,426,407.88, up 4.9% from ¥73,005,058.91 in the previous period[28] Cash Flow - The net cash flow from operating activities was -¥30,159,281.86, a decline of 131.03% compared to -¥13,054,229.29 in the same period last year[11] - Cash flow from operating activities showed a net outflow of ¥30,159,281.86, worsening from a net outflow of ¥13,054,229.29 in the previous period[36] - Cash inflow from investment activities was ¥87,908,000.00, a significant decrease from ¥563,300,400.00 in the previous period[36] - Cash outflow from investment activities totaled ¥63,552,640.76, down from ¥628,190,646.83 in the previous period[36] - Cash received from borrowings amounted to CNY 332.8 million, a decrease from CNY 360.4 million in the previous period[39] - Net cash flow from financing activities was negative CNY 70.3 million, improving from negative CNY 336.5 million year-over-year[39] - Cash and cash equivalents at the end of the period were CNY 243.3 million, down from CNY 303.9 million in the previous period[39] - Total cash outflow from financing activities was CNY 403.1 million, compared to CNY 699.1 million in the previous period[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,434,594,341.65, a decrease of 0.84% from ¥6,489,334,127.28 at the end of the previous year[4] - Current assets totaled CNY 3,492,203,956.37, slightly down from CNY 3,530,327,436.87 at the start of the year[18] - Cash and cash equivalents decreased to CNY 293,048,397.75 from CNY 465,625,063.55, representing a decline of approximately 37%[18] - Accounts receivable increased to CNY 1,695,183,495.47 from CNY 1,573,975,166.17, indicating a growth of about 7.7%[18] - Inventory rose to CNY 887,865,655.03 from CNY 844,793,857.87, reflecting an increase of approximately 5.1%[21] - Total liabilities decreased to CNY 2,408,955,206.13 from CNY 2,529,138,719.71, a reduction of about 4.8%[23] - The company's equity attributable to shareholders increased to CNY 4,006,385,961.27 from CNY 3,941,294,696.11, showing a growth of approximately 1.7%[23] - Short-term borrowings rose to CNY 1,519,999,971.11 from CNY 1,447,599,971.11, an increase of about 5%[21] Research and Development - The company's R&D expenses decreased by 65.13% to ¥4,085,372.30 from ¥11,714,628.78 in the same period last year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 171,695[12] - The largest shareholder, Jiang Wei, holds 24.17% of the shares, totaling 341,119,046 shares[12] Government Subsidies - The company received government subsidies amounting to ¥2,344,772.23, which were closely related to its normal business operations[5] Tax and Other Income - The company reported a tax expense of ¥11,458,420.05, compared to ¥10,856,725.46 in the previous period, reflecting an increase of approximately 5.5%[28] - Other income for the current period was ¥1,444,772.23, down from ¥2,036,307.40 in the previous period, indicating a decline of about 29%[28] Strategic Focus - The company is focusing on expanding its market presence and enhancing product development strategies[20] Audit Information - The company did not conduct an audit for the first quarter report[40]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[24]. - The net profit attributable to shareholders was RMB 300 million, which is a 10% increase compared to the previous year[24]. - The company's operating revenue for 2021 was ¥3,111,649,547.82, representing a 0.77% increase compared to ¥3,087,888,201.57 in 2020[32]. - The net profit attributable to shareholders for 2021 was ¥124,206,526.69, a decrease of 18.49% from ¥152,375,357.74 in 2020[32]. - The company reported a net profit of ¥3,536,233.62 in Q4 2021, a significant drop from Q3's ¥39,166,141.47[37]. - The company’s sales revenue for 2021 reached ¥1,056,229,105.89, representing a year-on-year increase of 10.47% compared to ¥956,137,482.87 in 2020[93]. - The industrial production revenue for 2021 was ¥1,216,220,219.67, showing a significant year-on-year growth of 29.05% from ¥942,445,558.7 in 2020[93]. - The company reported a total sales expense of ¥1,288,677,981.85 in 2021, which is a 13.49% increase from ¥1,135,453,538.93 in 2020[101]. - The company achieved a gross margin of 63.11% in the industrial sector, which is an increase of 0.56% from the previous year[90]. - The company reported a gross margin of 45%, maintaining a stable margin compared to the previous year[196]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 20% growth in international sales by 2023[24]. - The company aims to enhance its core market presence and sales management to achieve steady sales growth, focusing on both existing and new market opportunities[163]. - The company plans to expand its market presence by entering three new provinces in 2022, aiming for a 10% market share in these regions within the first year[196]. - The management provided a guidance of 15% revenue growth for 2022, driven by new product launches and market expansion efforts[196]. - The company is exploring potential acquisitions of smaller pharmaceutical firms to enhance its product portfolio and market reach[196]. Research and Development - Research and development expenses increased by 25% to RMB 150 million, focusing on new product development and technological advancements[24]. - The company is focusing on enhancing its research and development capabilities, particularly in the area of traditional Chinese medicine, to meet the growing demand for innovative healthcare solutions[50]. - The company applied for 7 patents in 2021, with 6 patents granted, indicating a strong focus on innovation and intellectual property[69]. - The company is committed to new drug research and development, focusing on products with high market potential and significant R&D barriers[64]. - Guizhou Bailing is investing 100 million CNY in R&D for new product development, focusing on innovative treatments for respiratory diseases[196]. Governance and Compliance - The company strictly adheres to the requirements of the Company Law and relevant regulations, ensuring compliance with corporate governance standards set by the China Securities Regulatory Commission (CSRC)[184]. - The company has established a complete governance structure, including a board of directors with 9 members, of which 4 are independent directors, exceeding one-third of the board[184]. - The company has established independent financial accounting and management systems, allowing it to make independent financial decisions and manage its finances without interference from the controlling shareholder[189]. - The company has a clear mechanism for selecting its management team, ensuring that all executives fulfill their duties responsibly and in the interest of shareholders[184]. Risks and Challenges - The management highlighted potential risks in the market, including regulatory changes and competition, which could impact future performance[24]. - The company faces risks in drug development due to long cycles, high investment, and significant uncertainties in clinical trials, which may lead to failures or delays[172]. - The pharmaceutical industry is heavily regulated in China, with ongoing policy changes that may impact drug pricing and sales volumes, posing risks to the company's revenue growth[172]. - Fluctuations in raw material prices, influenced by various macroeconomic factors, pose a risk to production costs[176]. Product Development and Innovation - The company is actively pursuing the integration of traditional Chinese medicine and modern healthcare, with its "Tang Ning Tong Luo" product gaining registration in multiple provinces and expanding its market presence[76]. - The company is developing new products, including a traditional Chinese medicine for chronic kidney disease, which is currently in phase II clinical trials[106]. - The company is conducting phase II clinical research for a new product aimed at treating oral ulcers and chronic gingivitis, which is nearing completion[106]. - The company is focusing on technological innovation and product development, with a commitment to increasing R&D investment to drive growth[81]. Financial Position and Assets - The total assets of the company reached RMB 3 billion, with a year-on-year growth of 12%[24]. - The total assets at the end of 2021 were ¥6,489,334,127.28, a decrease of 7.73% from ¥7,032,834,480.26 at the end of 2020[32]. - The net assets attributable to shareholders increased by 1.22% to ¥3,941,294,696.11 from ¥3,893,859,870.09 at the end of 2020[32]. - The company has a total of 1,534,032,512.63 yuan in restricted assets due to various pledges[119]. Marketing and Sales - The marketing network covers over 47,000 terminal customers nationwide, with more than 85,000 VIP clients signed, including over 4,500 secondary hospitals and 1,600 tertiary hospitals[73]. - The company has implemented new digital marketing strategies, resulting in a 40% increase in online sales channels[196]. - The company’s major customers accounted for 12.17% of total annual sales, with the top five customers generating a total sales amount of ¥378,600,395.94[98]. Investment and Projects - The company is currently involved in a self-built project in the pharmaceutical manufacturing industry with an investment of 143,146,340.28 yuan[123]. - The total investment for committed projects amounts to CNY 35,075.11 million, with CNY 50,278.04 million realized[134]. - The company has invested CNY 39,503.87 million in the traditional Chinese medicine production line and warehouse construction project, achieving 99.11% of the planned investment[138].

Financial Performance - The company's revenue for Q3 2021 was ¥704,889,897.55, a decrease of 4.14% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥39,166,141.47, down 25.30% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥33,621,138.31, a decline of 32.97% compared to the previous year[3]. - Total operating revenue for the current period is CNY 1,978,256,627.57, a decrease of 1.85% from CNY 2,015,826,955.79 in the previous period[28]. - Net profit for the current period is CNY 120,536,192.86, down 27.52% from CNY 166,321,739.92 in the previous period[30]. - The company reported a total comprehensive income attributable to shareholders of the parent company of CNY 161,034,023.90 for the current period[33]. Cash Flow - The operating cash flow net amount for the year-to-date was ¥306,399,352.57, an increase of 344.56%[3]. - Operating cash inflow for the current period was CNY 3,218,608,002.11, an increase from CNY 2,946,211,948.16 in the previous period, representing a growth of approximately 9.2%[35]. - The net cash flow from operating activities was CNY 306,399,352.57, significantly higher than CNY 68,921,209.04 in the previous period[35]. - Cash inflow from other operating activities was CNY 1,104,376,344.65, up from CNY 586,179,226.77, indicating an increase of about 88.0%[35]. - Cash inflow from financing activities was CNY 1,495,600,000.00, down from CNY 1,881,100,000.00, a decrease of approximately 21.0%[38]. - The net cash flow from financing activities was CNY -478,555,753.55, compared to CNY -276,577,403.31 in the previous period, indicating a decline in financing efficiency[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,583,868,678.22, a decrease of 6.38% from the end of the previous year[3]. - The company's current assets totaled CNY 3,817,419,540.32, down from CNY 4,595,047,400.33 in the previous year[21]. - The total liabilities decreased to CNY 2,643,222,751.80 from CNY 3,112,555,653.48, a reduction of 15.06%[24]. - Total liabilities reached approximately $3.11 billion, reflecting a decrease of $54.1 million from the prior period[47]. - Non-current liabilities totaled approximately $249.5 million, down from $303.6 million, indicating a reduction of $54.1 million[47]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 77,585[11]. - The top ten shareholders collectively hold a significant portion of the company, with the largest shareholder, Jiang Wei, owning 27.42%[16]. - The company reported a total of 13,601,600 shares held in the repurchase special securities account, representing 0.96% of total shares[17]. Research and Development - Research and development expenses increased by 101.10% to ¥23,868,023.89 compared to the same period last year[10]. - Research and development expenses increased to CNY 23,868,023.89, up from CNY 11,868,481.80 in the previous period, reflecting a growth of 100.06%[30]. Inventory and Receivables - Accounts receivable increased to CNY 1,611,430,297.00 from CNY 1,504,485,990.94 year-over-year, reflecting a growth of approximately 7.1%[18]. - Inventory rose to CNY 981,376,421.63, compared to CNY 783,540,559.49 in the previous year, indicating an increase of about 25.2%[21]. - The company experienced a 40.28% decrease in accounts receivable financing, totaling ¥355,917,923.83[7]. Other Financial Metrics - The weighted average return on net assets was 0.98%, down 0.35% year-on-year[3]. - Basic earnings per share for the current period is CNY 0.12, unchanged from the previous period[33]. - The company’s tax expenses for the current period are CNY 28,853,278.18, down from CNY 39,877,532.79 in the previous period[30]. Additional Notes - The company has implemented new leasing standards effective January 1, 2021, impacting financial statement adjustments[48]. - The third quarter report was not audited, indicating a potential area for further scrutiny[49].